Trial Profile

A Phase 1, Open-Label Study of ABSK021 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Solid Tumor

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pimicotinib (Primary)
Indications Carcinoma; Giant cell tumour of tendon sheath; Lung cancer; Pancreatic cancer; Sarcoma; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man
Sponsors Abbisko Therapeutics

Most Recent Events

22 May 2025 Planned number of patients changed from 85 to 276.
22 May 2025 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
22 May 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Dec 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com